Hevreng is one of Sweden’s highest ranked healthcare analysts, covering companies such as AstraZeneca, Sobi and Elekta. He has also covered Recipharm, Lifco and recently Medicover, when these companies went public. The position as Head of Research at Vator Securities implies that Hevreng will lead the firms fundamental research efforts.
“We are pleased to welcome Lars Hevreng to our research division. The appointment is effective as of 1 of March 2018. In his capacity, as one of the country's most reputable and top ranked analysts in the healthcare sector, Lars will contribute to our leading position as financial advisor to fast-growing companies that are planning an IPO at NASDAQ’s main board”, says Homan Panahi, CEO at Vator Securities.
Vator Securities provides an extensive range of capital markets and advisory services to cutting-edge public and private growth companies with an emphasis on the Life Sciences, Medical Technology and Diagnostics industries. Vator Securities executes on opportunities that accelerate growth for its client companies while delivering results to the firm’s sophisticated investor clientele.
“At Vator Securities I get to do what I love to do the most, which is driving growth for clients and working with the most innovative ideas within the industry. I look forward to develop Vator Securities’ research unit and to further strengthen our position as an innovative investment banking firm that fuels great ideas”, says Lars Hevreng.
For further information,
Homan Panahi, CEO, Vator Securities
Tel: +46 763-98 96 66